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The first-line therapy in metastatic renal cell carcinoma (mRCC), sunitinib, exhibits an objective response rate of
approximately 30%. Therapeutic alternatives such as other tyrosine kinase inhibitors, VEGF inhibitors, or mTOR
inhibitors emphasize the clinical need to predict the patient's response to sunitinib therapy before treatment
initiation. In this study, we evaluated the prognostic value of pretreatment portal venous phase contrast-enhanced
computed tomography (CECT) mean tumor density on overall survival (OS), progression-free survival (PFS), and
tumor growth in 63 sunitinib-treated mRCC patients. Higher pretreatment CECT tumor density was associated
with longer PFS and OS [hazard ratio (HR) = 0.968, P = .002, and HR = 0.956, P = .001, respectively], and CECT
density was inversely correlated with tumor growth (P = .010). Receiver operating characteristic analysis
identified two CECT density cut-off values (63.67 HU, sensitivity 0.704, specificity 0.694; and 68.67 HU, sensitivity
0.593, specificity 0.806) which yielded subpopulations with significantly different PFS and OS (P b .001).
Pretreatment CECT is therefore a promising noninvasive strategy for response prediction in sunitinib-treated
mRCC patients, identifying patients who will derive maximum therapeutic benefit.
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Kidney cancer is currently the 9th and 14th most common cancer in
men and women, respectively, and accounted for 143,000 deaths
worldwide in 2012 [1]. Renal cell carcinoma (RCC) accounts for
90% of kidney cancer cases, and its incidence is rising [2]. Due to its
nonspecific symptoms, renal cell carcinoma is often incidentally
diagnosed in unrelated imaging procedures, and metastases are
detected in 20% to 30% of the cases at the time of diagnosis [1].
Current clinical practice guidelines by the European Society of
Medical Oncology recommend the tyrosine kinase inhibitor sunitinib
as one of the first-line treatments for metastatic RCC (mRCC)
patients with good, intermediate, and poor prognosis [3,4].
Sunitinib-treated patients showed significantly longer progression-free
survival (PFS) and better quality of life compared to those treated with
interferon-alfa [5,6]. However, in light of an objective response rate of
only 31% [5], the pretreatment identification of patients with a highchance of benefitting from sunitinib therapy is an unmet clinical need
[3,7,8]. Alternative first-line treatments for mRCC patients include
other tyrosine kinase inhibitors such as pazopanib and sorafenib, the
VEGF-inhibitor bevacizumab (in combination with interferon-alfa),
and the mTOR-inhibitor temsirolimus [3,4].
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the Response Evaluation Criteria in Solid Tumors (RECIST) and
(revised) Choi criteria [3,9,10]. However, such assessment can only
be applied after several weeks of pharmacological treatment, which
potentially leads to a delay in the implementation of the most effective
treatment in nonresponders [3]. Furthermore, nonresponsive patients
risk a worse disease outcome, sunitinib-induced adverse reactions, and
higher treatment costs [3]. In the age of personalized medicine, there
is an unmet clinical need for new strategies to predict the therapeutic
benefit before treatment initiation in mRCC patients.
Several attempts for response prediction and treatment assessment
of antiangiogenic therapies have been undertaken, mostly based on
contrast-enhanced computed tomography (CECT), magnetic reso-
nance imaging, and ultrasound [7,11–21]. These imaging techniques
visualize the distribution of the contrast agent into the neoplastic
tissue, reflecting the vascularization of the tumor [22]. CECT is
currently the most clinically relevant technique, as arterial and portal
venous phase CECT are embedded in the assessment of treatment
response (Choi response criteria and their modifications, RECIST) in
mRCC patients receiving sunitinib [9,12,23,24].
A study by Han et al. found an association between arterial phase
CECT density before treatment and patient outcome in mRCCTable 1. Summary of Patient Characteristics
Total number of patients 63
Male 47 (74.6%)
Female 16 (25.4%)
Age (years), mean ± standard deviation 60.7 ± 11.3






25 mg 1 (1.6%)
37.5 mg 10 (15.9%)
50 mg 52 (82.6%)
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Xp11.2 translocation-type renal cell carcinoma, APSL-TFE3 variant 1 (1.6%)







Favorable risk 6 (9.5%)
Intermediate risk 42 (66.7%)
Poor risk 15 (23.8%)
Lesions 148
Lymph node 57 (35.5%)
Kidney 22 (14.9%)
Liver 15 (10.1%)








Lesion size (mm), mean ± standard deviation 42.5 ± 30.6patients under antiangiogenic therapy [11]. However, the patient
population of this study was small, and two different tyrosine kinase
inhibitors (sunitinib and sorafenib) were used [11]. In addition, the
investigated contrast enhancement phase, the arterial phase, is more
prone to hemodynamic biases and timing errors compared with the
portal venous phase [23]. Hence, we aim to investigate the
relationship between pretreatment mean CECT tumor density in
the portal venous phase and overall survival (OS), PFS, and tumor




Institutional review board approval and waiver for informed
consent were obtained for this retrospective study. Patients diagnosed
with mRCC receiving first-line sunitinib treatment at our institution
between October 1, 2008, and March 1, 2013, were selected for
analysis. The following inclusion criteria were used: mRCC patients
under sunitinib therapy and availability of baseline portal venous
phase CECT imaging of the thorax, abdomen, and pelvis carried out
within 4 weeks before treatment initiation and following two cycles of
treatment for response assessment. The following exclusion criteria
were applied: 1) unavailability of baseline or follow-up CECT images,
2) performance of either baseline or follow-up CECT without
intravenous contrast enhancement, 3) performance of a nonstan-
dardized or suboptimal CECT (e.g., inadequate scan coverage or
enhancement), 4) disease at baseline not measurable, 5) completion of
less than two cycles of sunitinib treatment, 6) patients who
underwent short cycles of sunitinib as neoadjuvant treatment before
surgical intervention rather than as maintenance therapy, and 7) lung
lesions because of the risk of air-filled cavitations in responding lung
lesions which were associated with skewed attenuation measurements
in the literature [10,25,26]. The same cohort was published before,
but the scope of the former study significantly differed from this
study [23].
CT Image Acquisition
CECT imaging of the abdomen, chest, and pelvis was performed
on all patients at baseline and after two cycles of sunitinib treatment
on a 16– or 128–detector row scanner (GE Lightspeed 16, GE
Healthcare; Somatom Definition Flash, Siemens). Iohexol (300 mg
iodine/ml, Omnipaque 300; GE Healthcare) was administered
intravenously (2 ml/kg body weight) by a power injector at a flow
rate adapted to cannula size (3 and 2 ml/s for 20 and 22 gauge,
respectively). Portal venous phase imaging was conducted cranio-
caudally using bolus tracking in the aorta with a threshold of 100 HU
(65- to 70-second delay, 120 kVp; 170-350 mAs; collimation, 0.6Table 2. Multivariate HRs for Death (OS) and Progression (PFS) Determined Using Multivariate
Cox Regression Analysis (n = 63)
Predictor β Std. Error HR 95% CI P Value
OS
Pretreatment mean CECT density −0.045 0.013 0.956 0.931-0.982 .001
Heng risk category (Intermediate risk) −0.798 0.406 0.450 0.203-0.997 .049
PFS
Pretreatment mean CECT density −0.032 0.011 0.968 0.948-0.989 .002
Age ≥ 62 years −0.846 0.316 0.429 0.231-0.797 .007
Figure 1. Comparison of a patient with low (A) and a patient with high pretreatment CECT tumor density (B). The female, 49-year-old
patient (A) with a low CECT tumor density before treatment initiation had a PFS time of 41 days and an OS time of 59 days. The female,
58-year-old patient (B) with a high pretreatment CECT tumor density in the kidney tumor and a mesenterial metastasis had a PFS time of
420 days and an OS time of 560 days.
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5-mm section thickness and 5-mm reconstruction increments.
Image Analysis
Target lesions were defined based on RECIST 1.1 criteria (five
target lesions, maximum of two lesions per organ) [27]. Lesions were
defined in consensus by two board-certified radiologist with
experience in oncological imaging of 13 (A.G.) and 8 years (Y.T.).
Unidimensional size and bidimensional attenuation were measured
on a single section that represented the largest diameter of each target
lesion. The sum of longest dimensions of all lesions was calculated as
defined by RECIST 1.1 criteria. The CT attenuation in Hounsfield
units of target lesions was determined by drawing a region of interest
around the lesion margin on the section selected for size measurement
at portal venous phase CT imaging, which gave the mean pixel
attenuation for each lesion. This was then averaged for all target
lesions to give a mean CT attenuation. The CT attenuation in
Hounsfield units of target lesions was determined by two
independent readers who drew a region of interest around the lesion
on the selected section on portal venous phase CT imaging. The thus
obtained mean pixel attenuation was subsequently averaged for allFigure 2. Scatterplots of pretreatment mean CECT tumor density an
CECT density shows a positive correlation with OS (Spearman's rh
P b .001, n = 63). An inverse correlation was determined for pretre
treatment cycles (posttreatment) and pretreatment (Spearman's rhotarget lesions. This attenuation was again averaged for both readers,
yielding a mean CT attenuation. The absolute and relative changes of
the sum of tumor diameters and the mean CECT attenuation from
the baseline (i.e., before treatment initiation) to the first follow-up
were calculated as evidence of tumor growth.
Statistical Analysis
Statistical software (R statistics 3.1.1 and SigmaPlot 13.0) was
employed for all statistical analyses. OS and PFS were chosen as the
two main outcome measures. OS and PFS were defined as the time
span between initiation of sunitinib treatment and death from any
cause or censorship at the date of last follow-up (OS) or date of
clinically documented tumor progression or death (whichever
occurred first) or censorship at the date of last follow-up (PFS). For
PFS, progression and death were defined as event. For both outcome
parameters, data collection was closed on June 25, 2013. To find the
hazard ratios (HRs) of responders to nonresponders for each set of
criteria, Cox regression analysis was carried out. First, univariate
analyses were performed for patient age, gender, previous nephrec-
tomy, Heng prognostic category (recoded binary: 1 = low and poor
risk; 2 = intermediate risk), Eastern Cooperative Oncology Groupd OS, PFS, and change in tumor size (n = 63). Pretreatment mean
o = 0.401, P = .001, n = 63) and PFS (Spearman's rho = 0.452,
atment mean CECT density and the ratio of tumor size after two
= −0.323, P = .010, n = 63).
Figure 3. ROC curve based on a PFS time of 250 days and boxplots of the OS and PFS time of subpopulations based on optimal
pretreatment mean CECT density cut-off points (n = 63). The ROC curve had an area under the curve of 0.722 (CI 0.595-0.849, P = .003,
n = 63, A). A Youden's index analysis yielded two optimal CECT density cut-offs (63.37 HU and 68.67 HU) associated with highly
significant differences in OS and PFS (P b .001, n = 63).
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and pretreatment mean CECT density. For categorical variables, the
log-rank test of equality across strata was done. For continuous
variables, Cox proportional hazard regression was calculated. All
predictors that had a P value b .2 in the univariate analyses were
considered for the final model of PFS (mean CT density, age, and
ECOG performance status) and OS (mean CT density, Heng
prognostic category, and ECOG performance status). The assump-
tion of log linearity was checked with linear splines. Age was
categorized using the median as cut point. Log minus log survival
curves were used to check the proportional hazards assumption.
ECOG performance status clearly did not meet this assumption and
was therefore used as strata variables in the final model. Spearman's
rho was calculated for the correlation between mean CECT tumor
density and OS, PFS, and the ratio of tumor size at first follow up
divided by tumor size pretreatment. A receiver operating character-
istic (ROC) analysis was carried out based on a PFS cut-off of 250
days, and Youden's index was employed to find optimal pretreatment
mean CECT tumor density cut-offs (OptimalCutpoints package, R
statistics). A nonparametric statistical test (Wilcoxon rank sum test)
was employed to investigate differences between the median OS or
the median PFS of the subgroups based on these cut-off values.
Furthermore, a Kaplan-Meier survival analysis with a log-rank test
was conducted. A P value of b .05 was deemed statistically significant.
Results
Baseline Characteristics
Of the 118 patients extracted from the database of our institution,
55 patients were excluded [unavailability of baseline or follow-up
CECT images (n = 18), performance of either baseline or follow-up
CECT without intravenous contrast enhancement (n = 14), perfor-
mance of a nonstandardized or suboptimal CECT (e.g., inadequate
scan coverage or enhancement) (n = 2), disease at baseline not
measurable (n = 7), completion of less than two cycles of sunitinib
treatment (n = 3), and patients who underwent short cycles ofsunitinib as neoadjuvant treatment before surgical intervention rather
than as maintenance therapy (n = 5), patients with lung lesions only
(n = 6), and all other lung lesions (15 lesions)]. Thus, 63 patients
with 148 lesions were included into the study and eligible for the
measurement of the CECT mean tumor density and tumor diameter.
The summary of the baseline characteristics of the patient population
is presented in Table 1.
Relationship of CECT and Survival
Portal venous phase mean CECT tumor density before treatment
was an independent predictor of PFS and OS [HR 0.968, 95%
confidence interval (CI) 0.948-0.989, P = .002, and HR 0.956, 95%
CI 0.931-0.982, P = .001, respectively; n = 63, number of events =
50; Table 2, Figures 1 and 2, A and B]. Pretreatment mean CECT
density in the portal venous phase was further inversely correlated
with tumor growth at first follow-up (Spearman's rho = −0.323, P =
.010, Figure 2C). Higher pretreatment portal venous phase mean
CECT density was therefore significantly associated with prolonged
PFS and OS and lower tumor growth at first follow-up (Figure 2).
A ROC analysis of the portal venous phase mean CECT tumor
density before treatment using a PFS cut-off of 250 days yielded an
area under the curve of 0.722 (standard error 0.065, CI 0.595-0.849,
P = .003; PFS b 250 days: 36 patients, PFS N 250 days: 27 patients;
Figure 3A). Using Youden's index, two optimal mean CT density
cut-off points were determined (cut-off 1: 63.67, sensitivity 0.704,
specificity 0.694, positive predictive value 0.633, negative predictive
value 0.758; cut-off 2: 68.67, sensitivity 0.593, specificity 0.806,
positive predictive value 0.696, negative predictive value 0.725). Both
cut-offs led to subpopulations with highly significantly different OS
and PFS (P b .001, n = 63; Figure 3, B-E). Kaplan-Meier survival
analysis showed significant differences in the OS and PFS for the
subpopulations of both cut-off values (P b .001, n = 63, Figure 4).
Discussion
The main finding of this study is that higher pretreatment portal
venous phase mean CECT tumor density was associated with longer
Figure 4. Kaplan-Meier survival curves for pretreatment cut-off 1 (A, B) and cut-off 2 (C, D; n = 63). Both cut-offs yield subpopulations
with significantly different OS and PFS curves (P b .001, n = 63) which highlights the usefulness of these two pretreatment mean CECT
density cut-off values in subgrouping mRCC patients according to their probability to respond to sunitinib treatment.
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.002 and P = .001, respectively) and that mean CECT tumor density
was inversely correlated with tumor growth after two treatment cycles
(P = .010). A ROC analysis based on a PFS of 250 days yielded two
mean CECT tumor density cut-off values with high sensitivity and
specificity which resulted in subpopulations with significantly
different survival outcomes (P b .001). These findings strongly
support the potential predictive value of portal venous phase
pretreatment mean CECT tumor density on the patient outcome
of mRCC patients receiving sunitinib. Mean CECT tumor density is
therefore a promising strategy for treatment stratification and a step
toward personalized medicine in mRCC patients.
In our study, we observed a linear correlation of portal
venous phase pretreatment mean CECT density with PFS and OS
[HR = 0.956 (P = .002) and HR = 0.968 (P = .001), respectively;
Table 2, Figure 2, A and B]. A very similar HR value was described byHan et al. in a comparison of the pretreatment mean CECT tumor
density in the arterial phase and PFS [11]. We therefore conclude that
the portal venous phase, which is less prone to timing artifacts and
hemodynamic biases, is of similar predictive value of disease outcome
in mRCC patients as the arterial phase. In contrast to the arterial
phase, which is primarily indicative the vascularity of the tumor, the
portal venous phase additionally represents the cellularity of the
neoplastic lesion [28]. Dense tumors on CECT are more cellular and
therefore necessitate a higher vascularization to grow, which renders
them more prone to antiangiogenic treatment [29].
Furthermore, our study demonstrated a positive correlation of the
portal venous phase pretreatment mean CECT tumor density and
tumor growth at first follow-up (P = .010, Figure 2C), which
demonstrates the strong association of pretreatment mean CECT
density with clinically used treatment response assessment criteria
relying on changes in tumor size [e.g., (revised) Choi or RECIST
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CECT density and tumor growth was described for the arterial phase
by Han et al. [11]. To the best of our knowledge, our study is the first
to show that portal venous CECT is of similar predictive value for the
clinical outcome in sunitinib-treated mRCC patients as arterial phase
imaging, and we believe that the higher robustness of portal venous
phase imaging strengthens the predictive value of assessing mean
CECT tumor density on the outcome of sunitinib therapy.
In accordance with the study by Han et al. [11], we grouped the
patients based on a PFS cut-off of 250 days. A ROC analysis yielded a
ROC area under the curve of 0.722 (P = .003, Figure 3A) which
corresponds well to the value reported by Han et al. [11]. Based on
Youden's index, two optimal cut-offs with high sensitivity and
specificity were determined: the first cut-off (63.67 HU) showed a
similarly high sensitivity and specificity (70.4% and 69.4%,
respectively). The second cut-off (68.67 HU) showed a very high
specificity and a good sensitivity (80.6% and 59.3%, respectively),
which underline its usefulness for identifying patients with lower
long-term benefits from sunitinib treatment. In contrast to Han et al.,
where four subgroups were created based on somewhat arbitrarily
chosen cut-off values [11], we decided to use a statistical method
(Youden's J statistic) to determine the optimal cut-off values and
created only two subgroups per cut-off value to facilitate clinical
application and validation. The subpopulations of both cut-off values
showed significant differences in PFS and OS (P b .001; Figure 3,
B-E). A Kaplan-Meier survival analysis yielded significantly different
survival curves for both PFS and OS (Figure 4, A-D), which
underlines the utility of these cut-off values in distinguishing patients
based on their probability of responding to treatment. We therefore
derived two pretreatment mean CECT density cut-off values with
high specificity and sensitivity associated with significant differences
in patient PFS and OS. These cut-off values provide valuable basis for
a more in-depth clinical validation.
Admittedly, our study had several limitations. Apart from its
retrospective design, the exclusion of 47% (55 of 118) may incur a
bias. Many patients who have not completed two treatment cycles
due to adverse reactions were excluded from this study to ensure that
our study investigates the efficacy of the sunitinib treatment in a
standardized fashion. Furthermore, patients with inadequate scans
and image quality had to be excluded as well. Moreover, certain
at-risk patient populations (e.g., renally insufficient patients) cannot
undergo CECT, and therefore, CECT attenuation measurements
cannot be performed on these subjects. In addition, portal venous
phase attenuation measurements are susceptible to changes in scan
parameters and interindividual differences in cardiovascular dynamics
(e.g., cardiac frequency and output). However, all included scans
followed the standardized CT imaging protocol used at our
institution. Moreover, methods yielding more direct measurements
of tumor vascularity (e.g., perfusion CT) necessitate changes in
imaging protocols and complex data analysis which may be difficult to
implement in routine clinical practice. Furthermore, the proposed
cut-off values may not be applicable in the context of a different
contrast agent dose. Future studies should aim at clarifying the impact
of potentially confounding factors such as cardiovascular parameters
and the contrast agent dose on contrast enhancement in the lesions.
Eventually, there was a slight variability in the timing of the baseline
CT scan (up to 4 weeks before treatment) and the first response
CT scan which was not avoidable due to the retrospective design of
the study.In summary, our study showed that higher pretreatment portal
venous phase mean CECT tumor density was associated with
prolonged PFS and OS (P = .002 and P = .001, respectively) in
mRCC patients undergoing sunitinib treatment and that high mean
CECT tumor density was associated with reduced tumor growth after
two treatment cycles (P = .010). Two optimal CECT tumor density
cut-off values with high specificity and sensitivity were established
which identified subpopulations with significantly different OS and
PFS (P b .001). The pretreatment mean CECT tumor density is
therefore a highly promising predictive and prognostic factor for the
treatment response of mRCC patients undergoing sunitinib therapy.
These findings support the use of this relatively simple measurement
to stratify treatment in mRCC patients, which represents a step
toward personalized medicine in this patient population.
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